GlassScriptPhysician profile
James D Torosis
NPI 1851477467
$6,076.34
in general payments reported to CMS, 2019-2025
26 companies · $1,803 in 2025
The $1,803 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $784 · 2020: $544 · 2021: $518 · 2022: $577 · 2023: $899 · 2024: $952 · 2025: $1,803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,654.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,774.02 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $751.03 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Madrigal Pharmaceuticals | $632.05 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $591.92 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $413.13 | 2019-2025 | Eohilia, Entyvio |
| Gilead Sciences, INC. | $354.70 | 2019-2025 | Livdelzi |
| Qol Medical, LLC | $234.51 | 2023-2025 | Sucraid, Sucraid |
| Pfizer INC. | $207.57 | 2023-2025 | |
| Braintree Laboratories, INC. | $176.36 | 2019-2023 | Suflave |
| Regeneron Healthcare Solutions, INC. | $174.98 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $170.71 | 2023-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $101.56 | 2019-2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $73.06 | 2019-2024 | |
| Celgene Corporation | $63.90 | 2021-2022 | |
| Genzyme Corporation | $53.24 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $49.67 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $45.97 | 2022-2025 | Ibsrela |
| Celltrion USA INC. | $41.34 | 2024 | Vegzelma |
| Janssen Scientific Affairs, LLC | $36.29 | 2020 | |
| Aimmune Therapeutics, INC. | $27.09 | 2023 | |
| Merck Sharp & Dohme LLC | $22.96 | 2024 | Dificid |
| Advanced Accelerator Applications | $21.45 | 2019 | |
| Novo Nordisk INC | $18.95 | 2025 | Wegovy |
| Cook Medical LLC | $17.58 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $11.82 | 2024 | Eyemx |
| Laborie Medical Technologies Corp. | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Torosis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.